Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Blood (2019) 134 (Supplement_1): 1711.

https://doi.org/10.1182/blood-2019-124978

Published: 2019

Journal Articles

Rituximab for Preventing Delayed Hemolytic Transfusion Reaction (DHTR) in Sickle CELL Adult Patients: Outcome of Transfusion and SIDE Effects in 58 CASES

Fabian Zanchetta-Balint, France Pirenne, MD PhD, Marc Michel, Armand Mekontso-Dessap, MD PhD, Matthieu Mahevas, MD, Constance Guillaud, MD, Keyvan Razazi, MD, Elena Foïs, MD, Frédéric Galactéros, MD PhD, Pablo Bartolucci, MD PhD, Anoosha Habibi

Blood (2019) 134 (Supplement_1): 3687.

https://doi.org/10.1182/blood-2019-130874

Published: 2019

Journal Articles

Impact of the Association between Tgl and EZH2 Mutations (Y641N/Y641F/Y641H/Y641S) on Disease Free Survival of Patients with Diffuse Large B-Cell Lymphoma

Myrna Candelaria, MD PharmD, Adriana Palacios Campos, MD, Olga Gutierrez Hernandez, QFB, Alejandro Aviles, MD, Uvi Cancino-Ramos, MD, Lucia Taja Chayeb, PhD, Osvaldo García-Perez, MD, David Cantú de León

Blood (2019) 134 (Supplement_1): 5222.

https://doi.org/10.1182/blood-2019-125906

Published: 2019

Journal Articles

A Risk Score Combined Clinical and Molecular Profiles Identifies a High-Risk Subgroup within Intermediate-Risk Acute Myeloid Leukemia

Xiaoxia Hu, Aijie Huang, Qi Chen, Ying Zhang, Lixia Liu, Chengcheng Wang, Weiping Zhang, Jianmin Yang, Jianmin Wang

Blood (2019) 134 (Supplement_1): 2713.

https://doi.org/10.1182/blood-2019-129186

Published: 2019

Journal Articles

A Prognostic Nomogram and Survival Analysis in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Shiyu Jiang, Yan Qin, Peng Liu, Jiangliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, Lin Gui, Changgong Zhang, Liqiang Zhou, Ming-Zhe Han, Yan Sun, Yuankai Shi, MD PhD

Blood (2018) 132 (Supplement 1): 2994.

https://doi.org/10.1182/blood-2018-99-116442

Published: 2018

Journal Articles

Quantitative Integrative Prediction of Survival Probability in Multiple Myeloma Using Molecular and Clinical Prognostic Factors in 657 Patients Treated with Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation

Manuela Hummel, Thomas Hielscher, Hans Jürgen Salwender, MD, Christof Scheid, Hans Martin, MD, Uta Bertsch, MD, Hartmut Goldschmidt, MD, Anja Seckinger, Dirk Hose, MD

Blood (2018) 132 (Supplement 1): 403.

https://doi.org/10.1182/blood-2018-99-113307

Published: 2018

Journal Articles

A 3-LncRNA Risk Scoring System for Prognosis of Adult Acute Myeloid Leukemia

Yuandong Feng, MD, Yachun Jia, Ying Shen, MD, Hongli Chen, Yue Peng, Ru Zhang, MD, Yun Yang, MD, Jian-Li Wang, MD PhD, Ju Bai, PhD, Fang-Xia Wang, MD PhD, Yan Xu, Aili He, MD

Blood (2018) 132 (Supplement 1): 5253.

https://doi.org/10.1182/blood-2018-99-114549

Published: 2018

Journal Articles

Lipid-Mediated Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample

Pauline van Paridon, BSc, Marina Panova-Noeva, Rene van Oerle, Andreas Schulz, Jürgen Prochaska, Natalie Arnold, Irene Schmidtmann, Manfred Beutel, Norbert Pfeiffer, Thomas Münzel, Karl J. Lackner, Tilman M. Hackeng, PhD, Hugo ten Cate, MD PhD, Philipp Wild, Henri M.H. Spronk, PhD

Blood (2018) 132 (Supplement 1): 1169.

https://doi.org/10.1182/blood-2018-99-116932

Published: 2018

Journal Articles

Unfractionated Heparin Use in Children: Clinical Outcomes in a Pediatric Cohort Managed Using an Anti-Factor Xa Based Nomogram

Surbhi Saini, MD, Katherine L Harsh, BS, Joseph R Stanek, MS, Sarah O'Brien, MD MSc, Amy L. Dunn, MD, Riten Kumar, MD MSc

Blood (2017) 130 (Supplement 1): 701.

https://doi.org/10.1182/blood.V130.Suppl_1.701.701

Published: 2017

Journal Articles

Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center

Lucia Masarova, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 4205.

https://doi.org/10.1182/blood.V130.Suppl_1.4205.4205

Published: 2017

Journal Articles

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Given after Standard Anticoagulant Therapy in Children (Two Age Groups: 1-<2 and 2-<12 Years Old), with Venous Thromboembolism

Jacqueline ML Halton, MD, Manuela Albisetti, MD, Matteo Luciani, Fenglei Huang, Branislav Biss, Martina Brueckmann, MD, Savion Gropper, MD, Hugo Maas, Igor Tartakovsky, MD, Lesley G Mitchell

Blood (2016) 128 (22): 87.

https://doi.org/10.1182/blood.V128.22.87.87

Published: 2016

Journal Articles

Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism

Jacqueline ML Halton, MD, Anne-Caroline Picard, Ruth Harper, Fenglei Huang, Martina Brueckmann, MD, Savion Gropper, MD, Hugo Maas, Igor Tartakovsky, MD, Ildar Nurmeev, Lesley G Mitchell, Leonardo R. Brandão, MD MSc, Manuela Albisetti, MD

Blood (2016) 128 (22): 1441.

https://doi.org/10.1182/blood.V128.22.1441.1441

Published: 2016

Journal Articles

Rationale and Design of a Phase IIb/III Open-Label, Multicenter Study of Dabigatran Etexilate for Venous Thromboembolism in Children: The Diversity Study

Manuela Albisetti, MD, Ivan Manastirski, Martina Brueckmann, MD, Savion Gropper, MD, Bushi Wang, Igor Tartakovsky, MD, Branislav Biss, Fenglei Huang, Lesley G Mitchell, MSc, Leonardo R. Brandão, MD MSc, Jacqueline ML Halton, MD

Blood (2016) 128 (22): 5025.

https://doi.org/10.1182/blood.V128.22.5025.5025

Published: 2016

Journal Articles

Rationale and Design of a Phase III Single-Arm Multicenter Study of Dabigatran Etexilate for the Secondary Prevention of Venous Thromboembolism in Children

Matteo Luciani, Manuela Albisetti, MD, Ivan Manastirski, Martina Brueckmann, MD, Savion Gropper, MD, Igor Tartakovsky, MD, Bushi Wang, Branislav Biss, Lesley G Mitchell, Fenglei Huang, Jacqueline ML Halton, MD, Leonardo R. Brandão, MD MSc

Blood (2016) 128 (22): 5028.

https://doi.org/10.1182/blood.V128.22.5028.5028

Published: 2016

Journal Articles

Creation of a Venous Thromboembolism Risk Prediction Tool for Critically Ill Children - the Cleveland Score

Minh Q Tran, MD, Steven L Shein, MD, Xinge Ji, MS, Kevin Chagin, MS, Hilda Ding, MD MS, Sanjay P Ahuja, MD, MSc

Blood (2016) 128 (22): 3803.

https://doi.org/10.1182/blood.V128.22.3803.3803

Published: 2016

Journal Articles

Pharmacokinetic and Pharmacodynamic (PKPD) Modeling to Determine the Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Direct Fxa Inhibitors

Leeds Janet, PhD, Genmin Lu, PhD, John T. Curnutte, MDPhD, Pamela B. Conley, PhD, Jaap W. Mandema, PhD

Blood (2015) 126 (23): 1135.

https://doi.org/10.1182/blood.V126.23.1135.1135

Published: 2015

Journal Articles

GSTA1 Genotype Influences Performance of Initial Bu Prediction Methods during Conditioning before SCT

Tiago Nava, MD, Marc Ansari, MD, Yves Theoret, PhD, Mohamed Aziz Rezgui, Samira Mezziani, Marie-France Vachon, Michel Duval, MD, Maja Krajinovic, PhD, Henrique Bittencourt, MD PhD

Blood (2015) 126 (23): 4323.

https://doi.org/10.1182/blood.V126.23.4323.4323

Published: 2015

Journal Articles

Efficacy and safety of Prothrombin Complex Concentrates Weight-Based Dosing for Reversal of Warfarin Anticoagulation

Rosanne St. Bernard, MD MSc, Kathleen Eckert, Alejandro Lazo-Langner, MD MSc, Ian H. Chin-Yee, MD FRCPC, Amanda Devraj, MD, Cyrus C. Hsia, BSc, MD FRCPC

Blood (2014) 124 (21): 4301.

https://doi.org/10.1182/blood.V124.21.4301.4301

Published: 2014

Journal Articles

IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era

Blood (2013) 122 (21): 362.

https://doi.org/10.1182/blood.V122.21.362.362

Published: 2013

Journal Articles

D-Dimer Levels Over Time and The Risk Of Recurrent Venous Thromboembolism: An Update Of The Vienna Prediction Model

Sabine Eichinger, MD, Georg Heinze, Paul A Kyrle, MD

Blood (2013) 122 (21): 462.

https://doi.org/10.1182/blood.V122.21.462.462

Published: 2013

NARROW

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Rituximab for Preventing Delayed Hemolytic Transfusion Reaction (DHTR) in Sickle CELL Adult Patients: Outcome of Transfusion and SIDE Effects in 58 CASES

Impact of the Association between Tgl and EZH2 Mutations (Y641N/Y641F/Y641H/Y641S) on Disease Free Survival of Patients with Diffuse Large B-Cell Lymphoma

A Risk Score Combined Clinical and Molecular Profiles Identifies a High-Risk Subgroup within Intermediate-Risk Acute Myeloid Leukemia

A Prognostic Nomogram and Survival Analysis in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Quantitative Integrative Prediction of Survival Probability in Multiple Myeloma Using Molecular and Clinical Prognostic Factors in 657 Patients Treated with Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation

A 3-LncRNA Risk Scoring System for Prognosis of Adult Acute Myeloid Leukemia

Lipid-Mediated Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample

Unfractionated Heparin Use in Children: Clinical Outcomes in a Pediatric Cohort Managed Using an Anti-Factor Xa Based Nomogram

Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Given after Standard Anticoagulant Therapy in Children (Two Age Groups: 1-<2 and 2-<12 Years Old), with Venous Thromboembolism

Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism

Rationale and Design of a Phase IIb/III Open-Label, Multicenter Study of Dabigatran Etexilate for Venous Thromboembolism in Children: The Diversity Study

Rationale and Design of a Phase III Single-Arm Multicenter Study of Dabigatran Etexilate for the Secondary Prevention of Venous Thromboembolism in Children

Creation of a Venous Thromboembolism Risk Prediction Tool for Critically Ill Children - the Cleveland Score

Pharmacokinetic and Pharmacodynamic (PKPD) Modeling to Determine the Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Direct Fxa Inhibitors

GSTA1 Genotype Influences Performance of Initial Bu Prediction Methods during Conditioning before SCT

Efficacy and safety of Prothrombin Complex Concentrates Weight-Based Dosing for Reversal of Warfarin Anticoagulation

IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era

D-Dimer Levels Over Time and The Risk Of Recurrent Venous Thromboembolism: An Update Of The Vienna Prediction Model

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only